John Moore

John Moore is a highly motivated scientist specializing in in vivo genome engineering techniques, including CRISPR/Cas9 and TALENS. As a Senior Director of Translational Gene Editing at Eli Lilly and Company, John leads multidisciplinary teams in developing nuclease-based therapeutic platforms. Previously, John held roles at 2seventy bio and Novo Nordisk, focusing on gene editing and in vivo therapies. John earned a Ph.D. in Biological and Biomedical Sciences from UMass Medical School and has contributed to research and teaching in various academic settings.